Skip to main content
Log in

Angelman syndrome

Drugs to awaken a paternal gene

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

Mutations in the maternal copy of the UBE3A gene cause a neurodevelopmental disorder known as Angelman syndrome. Drugs that activate the normally silenced paternal copy of this gene may be of therapeutic value. See Letter p.185

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Differential regulation of maternal and paternal UBE3A.

Notes

  1. *This article and the paper1 under discussion were published online on 21 December 2011.

References

  1. Huang, H.-S. et al. Nature 481, 185–189 (2011).

    Article  ADS  Google Scholar 

  2. Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Science 315, 1143–1147 (2007).

    Article  ADS  CAS  Google Scholar 

  3. Weeber, E. J. et al. J. Neurosci. 23, 2634–2644 (2003).

    Article  CAS  Google Scholar 

  4. Gammon, D. C. et al. Am. J. Health-Syst. Pharm. 63, 2083–2086 (2006).

    Article  CAS  Google Scholar 

  5. Bird, L. M. et al. Am. J. Med. Genet. A 155, 2956–2963 (2011).

    Article  ADS  CAS  Google Scholar 

  6. Williams, C. A., Driscoll, D. J. & Dagli, A. I. Genet. Med. 12, 385–395 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arthur L. Beaudet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beaudet, A. Drugs to awaken a paternal gene. Nature 481, 151–152 (2012). https://doi.org/10.1038/nature10784

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature10784

  • Springer Nature Limited

This article is cited by

Navigation